|
The Director of Cancer Research at Norwegian
Radium Hospital, and WaveSense’ CEO, present research
findings at 2006 AACR that validate EpiSep XRC™ methods
for detecting and characterizing tumor cells in lymph node
metastases.
The main objective of the collaboratative research
study, as presented by Hoifodt, Fodstad and Feistel, was to
evaluate EpiSep XRC™ as a quick and sensitive method
to detect, isolate and characterize tumor cells present in
lymph nodes, core biopsies of suspected malignancies or fine
needle aspirates. Such methods may be of significant practical
value in the assessment of disease stage, prognosis and possibly
in determining optimal therapy. The ability to characterize
the isolated tumor cells would make it possible to assess
their expression of clinically relevant tumor-associated antigens
and biomarkers.
Dr. Oystein Fodstad and Dr. Hanne Kleppe Hoifodt are affiliated
with the Dept. of Tumor Biology, The Norwegian Radium Hospital
in Oslo, Norway, and Dr. Fodstad is also with the University
of South Alabama, Mitchell Cancer Research Institute in Mobile,
AL. Dr.’s Fodstad and Hoifodt are regarded as world
leading authorities in the field of magnetic capture and isolation
of tumor cells. Professor Fodstad is the Chairman of WaveSense’s
Scientific Advisory Board.
The products described in this announcement
are for research use only and not intended for diagnostic
or therapeutic purposes.
View EpiSep XRC™ - How
It Works
|
